Esatenolol

Esatenolol is the (S)-enantiomer of atenolol, a well-known cardioselective beta-1 adrenergic antagonist. As a beta-blocker, its mechanism of action involves selectively binding to and blocking beta-1 adrenergic receptors, primarily located in the heart. This blockade inhibits the effects of endogenous catecholamines like isoproterenol, norepinephrine, and epinephrine, leading to a reduction in heart rate, blood pressure, and myocardial contractility. Esatenolol is a small molecule drug that has reached a maximum clinical trial phase of II for at least one investigational indication.

Other names

(S)-Atenolol(-)-AtenololS-AtenololAtenolol, (s)-Atenolol, (-)-2-(p-((2S)-2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamideS-(-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide(S)-4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide2-[4-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamideBenzeneacetamide, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, (S)-CHEBI:31556DTXSID10239405DTXSID-10239405DTXSID 102394052-[4-({(2S)2-hydroxy-3-[(propan-2-yl)amino]propyl}oxy)phenyl]acetamideesatenololum2-(4-((2S)-2-hydroxy-3-(propan-2-ylamino)propoxy)phenyl)acetamideAtenolol